Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma

Oral Oncology

Volumn 46, Issue 5, 2010, Pages 323-329

  Iglesias Linares, A ^a   Yanez Vico R M ^a   Gonzalez Moles M A ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Epigenetics; HDAC inhibitors; HDACs; Head and neck cancer; Histone deacetylases; Oral cancer

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ASN 02; CISPLATIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

CANCER THERAPY; DRUG MECHANISM; ENZYME POLYMORPHISM; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS;

EID: 77950865895     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.01.009     Document Type: Review

References (71)

1. Morales V., Giamarchi C., Chailleux C., Moro F., Marsaud V., Le Ricousse S., et al. Chromatin structure and dynamics: functional implications. Biochimie 83 (2001) 1029-1039
2. Kornberg R.D., and Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98 (1999) 285-294
3. Becker P.B., and Horz W. ATP-dependent nucleosome remodeling. Annu Rev Biochem 71 (2002) 247-273
4. Lusser A., and Kadonaga J.T. Chromatin remodeling by ATP-dependent molecular machines. Bioessays 25 (2003) 1192-1200
5. Bernstein B.E., Meissner A., and Lander E.S. The mammalian epigenome. Cell 128 (2007) 669-681
6. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
7. Roth S.Y., Denu J.M., and Allis C.D. Histone acetyltransferases. Annu Rev Biochem 70 (2001) 81-120
8. Cress W.D., and Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184 (2000) 1-16
9. Ng H.H., and Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci 25 (2000) 121-126
10. Grozinger C.M., and Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9 (2002) 3-16
11. Verdin E., Dequiedt F., and Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet 19 (2003) 286-293
12. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
13. Glozak M.A., and Seto E. Histone deacetylases and cancer. Oncogene 26 (2007) 5420-5432
14. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38 (2006) 566-569
15. Miyake K., Yoshizumi T., Imura S., Sugimoto K., Batmunkh E., Kanemura H., et al. Expression of hypoxia-inducible factor-1a, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36 (2008) e1-e9
16. Choi J.H., Kwon H.J., Yoon B.I., Kim J.H., Han S.U., Joo H.J., et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92 (2001) 1300-1304
17. Weichert W., Roske A., Gekeler V., Beckers T., Ebert M.P., Pross M., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9 (2008) 139-148
18. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7 (2006) 90
19. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14 (2008) 1669-1677
20. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., and Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59 (2004) 177-189
21. Rikimaru T., Taketomi A., Yamashita Y., Shirabe K., Hamatsu T., Shimada M., et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72 (2007) 69-74
22. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46 (2004) 171-178
23. Krusche C.A., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 90 (2005) 15-23
24. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94 (2005) 11-16
25. Katsura T., Iwai S., Ota Y., Shimizu H., Ikuta K., and Yura Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 16 (2009) 237-245
26. Sato T., Suzuki M., Sato Y., Echigo S., and Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28 (2006) 1233-1241
27. Rikiishi H., Shinohara F., Sato T., Sato Y., Suzuki M., and Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 30 (2007) 1181-1188
28. Suzuki M., Endo M., Shinohara F., Echigo S., and Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64 (2009) 1115-1122
29. Yao J., Duan L., Fan M., and Wu X. NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by trichostatin A in human tongue carcinoma cells. Pharmacol Res 54 (2006) 406-413
30. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21 (2002) 2672-2681
31. Senese S., Zaragoza K., Minardi S., Muradore I., Ronzoni S., Passafaro A., et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27 (2007) 4784-4795
32. Keshelava N., Davicioni E., Wan Z., Ji L., Sposto R., Triche T.J., et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 99 (2007) 1107-1119
33. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12 (2005) 395-404
34. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98 (2008) 604-610
35. Chang H.H., Chiang C.P., Hung H.C., Lin C.Y., Deng Y.T., and Kuo M.Y. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 45 (2009) 610-614
36. Harms K.L., and Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67 (2007) 3145-3152
37. Bicaku E., Marchion D.C., Schmitt M.L., and Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 68 (2008) 1513-1519
38. Atsumi A., Tomita A., Kiyoi H., and Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARa as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345 (2006) 1471-1480
39. Amann M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21 (2001) 6470-6483
40. Oehme I., Deubzer H.E., Wegener D., Pickert D., Linke J.P., Hero B., et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15 (2009) 91-99
41. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., et al. Crystal structure of a eukaryotic zinc dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101 (2004) 15064-15069
42. Lee H., Sengupta N., Villagra A., Rezai-Zadeh N., and Seto E. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin mediated degradation. Mol Cell Biol 26 (2006) 5259-5269
43. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., and Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 (2008) 1026-1034
44. Mottet D., Bellahcene A., Pirotte S., Waltregny D., Deroanne C., Lamour V., et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101 (2007) 1237-1246
45. Chauchereau A., Mathieu M., de Saintignon J., Ferreira R., Pritchard L.L., Mishal Z., et al. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia associated protein PLZF. Oncogene 23 (2004) 8777-8784
46. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., et al. Class II histone deacetylases are associated with VHL independent regulation of hypoxia-inducible factor 1a. Cancer Res 66 (2006) 8814-8821
47. Watamoto K., Towatari M., Ozawa Y., Miyata Y., Okamoto M., Abe A., et al. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22 (2003) 9176-9184
48. Sakuma T., Uzawa K., Onda T., Shiiba M., Yokoe H., Shibahara T., et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29 (2006) 117-124
49. Zhang Z., Yamashita H., Toyama T., Sugiura H., Omoto Y., Ando Y., et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10 (2004) 6962-6968
50. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100 (2003) 4389-4394
51. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280 (2005) 26729-26734
52. Li Y., Zhang X., Polakiewicz R.D., Yao T.P., and Comb M.J. HDAC6 is required for EGF-induced β-catenin nuclear localization. J Biol Chem 283 (2008) 12686-12690
53. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368 (2008) 318-322
54. Shan B., Yao T.P., Nguyen H.T., Zhuo Y., Levy D.R., Klingsberg R.C., et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 283 (2008) 21065-21073
55. Feng W., Lu Z., Luo R.Z., Zhang X., Seto E., and Liao W.S. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer 120 (2007) 1664-1668
56. Voelter-Mahlknecht S., Ho A.D., and Mahlknecht U. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. Int J Mol Med 16 (2005) 589-598
57. Lindberg D., Akerström G., and Westin G. Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol (Oxf) 66 (2007) 110-114
58. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578-3588
59. Kelly W.K., O'Connor O.A., and Marks P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11 (2002) 1695-1713
60. Piekarz R., and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10 (2004) 2289-2298
61. Qiu L., Kelso M.J., Hansen C., West M.L., Fairlie D.P., and Parsons P.G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80 (1999) 1252-1258
62. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165-5170
63. Atadja P., Gao L., Kwon P., Trogani N., Walker H., Hsu M., et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64 (2004) 689-695
64. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
65. Murakami J., Asaumi J., Maki Y., Tsujigiwa H., Kuroda M., Nagai N., et al. Effects of demethylating agent 5-aza-2(′)-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol 40 (2004) 597-603
66. Murakami J., Asaumi J., Kawai N., Tsujigiwa H., Yanagi Y., Nagatsuka H., et al. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol 56 (2005) 22-28
67. Chung Y.L., Lee M.Y., and Pui N.N. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30 (2009) 1387-1397
68. Shen J., Huang C., Jiang L., Gao F., Wang Z., Zhang Y., et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73 (2007) 1901-1909
69. Druesne N., Pagniez A., Mayeur C., Thomas M., Cherbuy C., Duee P.H., et al. Diallyl disulfide (DADS) increases histone acetylation and p21waf1/cip1 expression in human colon tumor cell lines. Carcinogenesis 25 (2004) 1227-1236
70. Myzak M.C., Karplus P.A., Chung F.L., and Dashwood R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64 (2004) 5767-5774
71. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 25 (2003) 191-196